Conversation with The Cancer LetterFree We ask FDA to explain “dangling” accelerated approvals—and this week’s ODAC agenda April 30, 2021Vol.47 No.17By Paul Goldberg
Conversation with The Cancer Letter We ask MIT’s Vander Heiden to delineate science from engineering—and NCI from ARPA-H“The lines are much more blurred in terms of what’s an engineering problem and what’s a basic science problem.” April 23, 2021Vol.47 No.16By Matthew Bin Han Ong and Paul Goldberg
Conversation with The Cancer LetterFree Karen Knudsen named CEO of the American Cancer Society April 12, 2021Vol.47 No.15By Paul Goldberg
Conversation with The Cancer Letter Robert Stone: City of Hope aims to transform cancer care nationally through new models, partnerships April 02, 2021Vol.47 No.13By Paul Goldberg
Conversation with The Cancer Letter Targeted therapies and better outcomes for small cell lung cancer? NCI study on actionable germline mutations finds a link March 26, 2021Vol.47 No.12By Matthew Bin Han Ong
Cancer History ProjectConversation with The Cancer LetterFree NCCN’s Bob Carlson talks about the day he stormed out of a meeting with transplanters March 26, 2021Vol.47 No.12By Paul Goldberg
Cancer History ProjectConversation with The Cancer LetterFree Bill McGivney: How NCCN guidelines came to play a role in payment for cancer therapy March 19, 2021Vol.47 No.11By Paul Goldberg
Conversation with The Cancer Letter Working in concert with NCI’s $500M data federation in childhood cancer, St. Jude demonstrates utility of its genomic database March 12, 2021Vol.47 No.10By Matthew Bin Han Ong
Cancer History ProjectConversation with The Cancer LetterFree Bob Young: NCCN is a case study in keeping what works and discarding what doesn’t March 12, 2021Vol.47 No.10By Paul Goldberg
Conversation with The Cancer Letter Not for sale: Fox Chase Cancer Center March 05, 2021Vol.47 No.09By Paul Goldberg
